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Abstract 1 
In vitro batch culture fermentations were conducted with grape seed polyphenols and 2 
human faecal microbiota, in order to monitor both changes in precursor flavan-3-ols as 3 
well as the formation of microbial-derived metabolites. By the application of UPLC-4 
DAD-ESI-TQ MS, monomers, dimeric and trimeric procyanidins, were shown to be 5 
degraded during the first 10 h of fermentation, with notable inter-individual differences 6 
being observed between fermentations. This period (10 h) also coincided with the 7 
maximum formation of intermediate metabolites such as 5-(3’,4’-dihydroxyphenyl)- -8 
valerolactone and 4-hydroxy-5-(3’,4’-hydroxyphenyl)-valeric acid, and of several 9 
phenolic acids, including 3-(3,4-dihydroxyphenyl)-propionic acid, 3,4-10 
dihydroxyphenylacetic acid, 4-hydroxymandelic acid, and gallic acid (5-10 h maximum 11 
formation). Later phases of the incubations (10-48 h) were characterized by the 12 
appearance of mono- and non-hydroxylated forms of previous metabolites by 13 
dehydroxylation reactions. Of particular interest was the detection of -valerolactone, 14 
which was seen for the first time as a metabolite from the microbial catabolism of 15 
flavan-3-ols. Changes registered during fermentation were finally summarized by a 16 
principal component analysis (PCA). Results revealed that 5-(3’,4’-dihydroxyphenyl)- -17 
valerolactone was a key metabolite in explaining inter-individual differences and 18 
delineating the rate and extent of the microbial catabolism of flavan-3-ols, which could 19 
finally affect absorption and bioactivity of these compounds. 20 
21 
 3 
INTRODUCTION 1 
 2 
Over the last decade, a number of epidemiological and interventional studies have 3 
demonstrated that there may be an association between polyphenol consumption and 4 
human health (Arts, Jacobs Jr, Harnack, Gross & Folsom, 2001; Hertog, Feskens & 5 
Kromhout, 1997; Knekt et al., 2000). However, before exhibiting their activity in the 6 
human organism, polyphenols need to be bioavailable. Therefore, bioavailability is a 7 
key issue linking food polyphenols and human health. Many polyphenols present poor 8 
absorption in the small intestine but are metabolized by the colonic microbiota into 9 
simple phenolic compounds that could be further absorbed (Aura, 2008; Selma, Espín & 10 
Tomás-Barberán, 2009; Williamson & Clifford, 2010). A recent study in ileostomy 11 
subjects has estimated that around 70% of a green tea intake is present in ileal fluid 12 
(Stalmach, Mullen, Steiling, Williamson, Lean & Crozier, 2010), confirming that, in 13 
general, the amount of non-absorbable polyphenols reaching the colon is high and that 14 
microbial-derived phenolic metabolites must be partly responsible for phenolic-15 
associated health benefits (Williamson et al., 2010). Among these non-absorbable 16 
polyphenols are flavan-3-ols, in particular their oligomeric and polymeric forms or 17 
proanthocyanidins, which are very abundant in wine, grape, cocoa, apple, and nut skins, 18 
among other sources (Manach, Scalbert, Morand, Rémésy & Jiménez, 2004). 19 
Bioavailability of flavan-3-ols is influenced by the degree of polymerization (DP). 20 
Monomeric flavan-3-ols are readily absorbed in the small intestine, dimeric 21 
procyanidins present low absorption, whereas oligomeric (DP 3) and polymeric forms 22 
require activities by the colonic microbiota in order to be absorbed and further 23 
metabolized (Déprez et al., 2000; Gonthier, Donovan, Texier, Felgines, Remesy & 24 
Scalbert, 2003b; Monagas et al., 2010). Moreover, the colonic microbiota also plays an 25 
 4 
important role in the overall bioavailability of the absorbable-flavan-3-ol fraction, since 1 
these compounds also reach the colon by enterohepatic recirculation as phase II 2 
conjugates that are deconjugated and further catabolized by the microbiota. The colonic 3 
metabolism of flavan-3-ols is complex and despite enormous effort being devoted to 4 
this area in recent years, catabolic pathways are still under elucidation (Appeldoorn, 5 
Vincken, Aura, Hollman & Gruppen, 2009; Stoupi, Williamson, Drynan, Barron & 6 
Clifford, 2010) and the bacteria responsible have not been identified yet. Although 7 
many of the final microbial metabolites are common to those formed by the catabolism 8 
of other flavonoids, which mainly includes phenylacetic, phenylpropionic and benzoic 9 
acids of different degree of hydroxylation, intermediate metabolites such as 5-(3’,4’-10 
dihydroxyphenyl)- -valerolactone and 4-hydroxy-5-(3’,4’-hydroxyphenyl)-valeric acid,  11 
are characteristics of the catabolism of flavan-3-ols but often overlooked. However, 12 
recent studies have indicated that their occurrence and residence time in humans 13 
deserves consideration for possible local or systemic effects (Garrido et al., 2010; 14 
Llorach et al., 2010). Although the bioactivity of microbial catabolites are still largely 15 
unknown, in particular in their actual conjugated form, evidence related to the 16 
antioxidant, anti-inflammatory and anti-proliferative effects of  5-(3,4-17 
dihydroxyphenyl)- -valerolactone have been reported (Grimm, Schäfer & Hoögger, 18 
2004; Lambert, Rice, Hong, Hou & Yang, 2005). Concerning microbial-derived 19 
phenolic acids, antioxidant, anti-thrombotic, anti-inflammatory and anti-proliferative 20 
activities, as well as inhibition of pathogenic bacteria and modulation of lipid 21 
metabolism, have been described (Monagas et al., 2010).  22 
 23 
Studies on the microbial catabolism of grape or wine flavan-3-ols (Gross et al., 2010; 24 
Grün et al., 2008; van Dorsten, Grün, van Velzen, Jacobs, Draijer & van Duynhoven, 25 
 5 
2009; Ward, Croft, Puddey & Hodgson, 2004) or individual monomeric flavan-3-ols 1 
and dimeric procyanidins (Appeldoorn et al., 2009; Kohri, Suzuki & Nanjo, 2003; 2 
Meselhy, Nakamura & Hattori, 1997; Roowi, Stalmach, Mullen, Lean, Edwards And & 3 
Crozier, 2010; Stoupi et al., 2010; Takagaki & Nanjo, 2010; van't Slot & Humpf, 2009), 4 
have been carried out. Most of these studies have monitored the formation of 5 
metabolites during the time-course of fermentation but rarely have concurrently studied 6 
disappearance of the original substrate or precursor compounds. The aim of the present 7 
work was to conduct in vitro batch fermentation experiments of a grape seed extract 8 
with human faecal microbiota in order to assess both changes in non-galloylated and 9 
galloylated monomeric, dimeric and trimeric precursor flavan-3-ols, as well as the 10 
formation of a wide range of intermediate and final microbial metabolites derived from 11 
flavan-3-ol catabolism.  12 
 13 
MATERIALS AND METHODS 14 
 15 
Materials 16 
Standards of phenolic compounds were purchased from Sigma-Aldrich Chemical Co 17 
(St. Loius, MO), Phytolab (Vestenbergsgreuth, Germany) or Extrasynthèse (Genay, 18 
France). Vitaflavan® extract obtained from grape seeds was kindly provided by Les 19 
Dérives Resiniques & Terpéniques (DRT), S.A. (France). LC grade solvents were 20 
purchased from Lab-Science (Sowinskiego, Poland) or from Scharlau (Barcelona, 21 
Spain). Bacteriological growth media supplements were obtained from Oxoid Ltd 22 
(Basingstoke, Hants, UK). The remaining chemicals and reagents were obtained either 23 
from Sigma-Aldrich Co. Ltd (Poole, Dorset, UK) or Fisher (Loughborough, Leics, UK) 24 
 25 
 6 
Faecal sample preparation 1 
Faecal samples were collected from three different individuals. All volunteers were in 2 
good health and had not been given antibiotics for at least 6 months before the study. 3 
Samples were collected, on site, on the day of the experiment and were used 4 
immediately. Samples were diluted 1:10 (w/v) with anaerobic phosphate buffer (1 M; 5 
pH 7.2) and homogenized in a stomacher for 2 min. Resulting faecal slurries from each 6 
individual (i.e. faecal samples were not pooled) were used to inoculate batch-culture 7 
vessels.  8 
 9 
Batch-culture fermentations 10 
Batch-culture fermentation vessels (300 ml volume; one vessel per treatment group) 11 
were sterilized and filled with 135 ml basal nutrient medium (peptone water (2 g/l), 12 
yeast extract (2 g/l), NaCl (0.1 g/l), K2HPO4 (0.04 g/l), KH2PO4 (0.04 g/l), NaHCO3 (2 13 
g/l), MgSO4.7H2O (0.01 g/l), CaCl2.6H2O (0.01 g/l), Tween 80 (2 ml/l), hemin (50 14 
mg/l), vitamin K (10 l/l), L-cysteine (0.5 g/l), bile salts (0.5 g/l), resazurin (1 mg/l) and 15 
distilled water). The pH of the basal medium was adjusted to 7.0 and autoclaved before 16 
dispensing it to the vessels. Medium was then gassed overnight (15mL/min) with O2-17 
free N2. Before the addition of faecal slurry samples, temperature of the basal nutrient 18 
medium was set to 37ºC by using a circulating water-bath and the pH was maintained at 19 
6.8, using an Electrolab pH controller, in order to mimic conditions in the distal region 20 
of the human large intestine (anaerobic; 37ºC; pH about 6.8). Vessels were inoculated 21 
with 15 ml faecal slurry (1:10, w/v) and then Vitaflavan® grape seed extract (Table 1) 22 
was added at a concentration of 600 mg/l. Batch cultures were run under anaerobic 23 
conditions for a period of 48 h during which samples were collected at six time points 24 
(0, 5, 10, 24, 30, and 48 h) in sterile Eppendorf tubes (1.5 ml). Two different control 25 
 7 
experiments were conducted: a) incubations of the faecal microbiota in medium, but 1 
lacking the grape seed extract, to monitor metabolites arising from basal metabolism; b) 2 
incubations of the grape seed extract in medium but without faecal microbiota, to 3 
monitor changes due to the non-microbial chemical transformation of precursor 4 
compounds of the substrate. Samples were stored at -70ºC until required for the analysis 5 
of phenolic compounds by UPLC-PAD-ESI-TQ MS. Before injection, samples were 6 
defrosted, centrifuged (14926 g, 20 ºC, 10 min) and filtered through a 0.22 µm PVDF 7 
filter (Teknokroma, Barcelona, Spain), and finally diluted (1:1, v/v) with a mixture of 8 
water/acetonitrile (6:4, v/v).  9 
 10 
Analysis of phenolic precursors and microbial metabolites by UPLC-DAD-ESI-TQ 11 
MS 12 
An UPLC system coupled to a Acquity PDA eλ photodiode array detector (DAD) and 13 
a Acquity TQD tandem quadrupole mass spectrometer equipped with Z-spray 14 
electrospray interfece (UPLC-DAD-ESI-TQ MS) (Waters, Milford, MA, USA) was 15 
used. Separation (2 μL) was performed on a Waters  BECH C18 column (2.1 x 100 16 
mm; 1.7 m) at 40ºC. A gradient composed of solvent A- water:acetic acid (98:2, v/v) 17 
and B-acetonitrile:acetic acid (98:2, v/v) was applied at flow rate of 0.5 mL/min as 18 
follows: 0-1.5 min: 0.1% B, 1.5-11.17 min: 0.1-16.3% B, 11.17-11.5 min: 16.3-18.4% 19 
B, 11.5-14 min: 18.4% B, 14-14.1 min: 18.4-99.9% B, 14.1-15.5 min: 99.9% B, 15.5-20 
15.6 min: 0.1% B, 15.6-18 min: 0.1% B.  The DAD was operated in the 250-420 nm 21 
wavelength range at a 20 point/s rate and 1.2 nm resolution. The ESI parameters were: 22 
Capillary voltage, 3 kV; source temperature, 130 C; desolvation temperature, 400 C; 23 
desolvation gas (N2) flow rate, 750 L/h; cone gas (N2) flow rate, 60 L/h. The ESI was 24 
operated in negative mode, except for -valerolactone which was operated in positive 25 
 8 
mode. For quantification purposes, data were collected in the multiple reaction 1 
monitoring (MRM) mode, tracking the transition of parent and product ions specific 2 
for each compound, and using external calibration curves. For microbial phenolic 3 
metabolites, MRM transitions were those described by Sánchez-Patán et al. (Sánchez-4 
Patán, Monagas, Moreno-Arribas & Bartolomé, 2011). For phenolic precursors in the 5 
both grape seed extract and culture samples, the MS parameter optimization, MRM 6 
transitions, tested concentration range, and  limits of detection and quantification are 7 
summarized in Table 2. MRM transitions of other metabolites studied were: 1-(3’,4’-8 
dihydroxyphenyl)-3-(2”, 4”, 6”-trihydroxyphenyl)-propan-2-ol (291/247); 1-9 
(hydroxyphenyl)-3-(2”, 4”, 6”-trihydroxyphenyl)propan-2-ol (275/231); 5-(3’,4’-10 
dihydroxyphenyl)- -valerolactone (207/163); 5-(3’-hydroxyphenyl)- -valerolactone 11 
(191/147); 5-(phenyl)- -valerolactone (175/147); -valerolactone (101/55); 4-hydroxy-12 
5-(3’,4’-dihydroxyphenyl)-valeric acid (225/163); 4-hydroxy-5-(3’-hydroxyphenyl)-13 
valeric acid (209/147); 4-hydroxy-5-(phenyl)-valeric acid (193/175). Quantification of 14 
procyanidin B2 and B3 was carried out in function of the calibration curve of 15 
procyanidin B1. Procyanidins B1-3-O-gallate, B2-3-O-gallate and B2’-3-O-gallate 16 
were quantified using the (-)-epicatechin-3-O-gallate curve. Phenyl- -valerolactones 17 
derivatives were quantified as (-)-epicatechin and -valerolactone using its on 18 
calibration curve. 4-Hydroxy-5-(3’,4’-dihydroxyphenyl)-valeric and 4-hydroxy-5-(3’-19 
hydroxyphenyl)-valeric acids were quantified using the calibration curves of 3-(3,4-20 
dihydroxyphenyl)-propionic and 3-(3-hydroxyphenyl)-propionic acids, respectively. 21 
Table 2 reports limit of detection (LOD) and limit of quantification (LOQ) of the 22 
flavan-3-ol standards used. For phenolic acids and other related phenolic compounds, 23 
LOD and LOQ data under these analytical conditions are reported elsewhere (Sánchez-24 
Patán et al., 2011). LOD and LOQ for -valerolactone were calculated as 0.035 and 25 
 9 
0.100 μg/mL, respectively. Data acquisition and processing was carried out using 1 
MassLynx 4.1. software.  2 
 3 
Statistical analysis 4 
The statistical methods used for data processing were: simple regression to study the 5 
time-course degradation of one of the volunteers using a logarithmic-Y square root-X 6 
model (Y= exp (a + b* sqrt(X)) and the STATGRAPHICS Centurion XV program for 7 
Windows, version 15.2.00 (StatPoint Inc. 1982-2006, www.statgraphics.com);  and 8 
principal component analysis (PCA), from standardized variables, to summarize 9 
changes in the concentration of both precursor flavan-3-ols and microbial phenolic 10 
metabolites resulting from the batch culture fermentation of the grape seed extract, with 11 
the STATISTICA program for Windows, version 7.1 (StatSoft. Inc. 1984–2006, 12 
www.statsoft.com).   13 
 14 
RESULTS AND DISCUSSION 15 
Changes in precursor phenolic compounds during faecal fermentation of the grape 16 
seed extract 17 
 18 
Phenolic composition of the grape seed extract used in this study is summarized in 19 
Table 1. It was mainly composed of flavan-3-ols including: non-galloylated monomers 20 
(+)-catechin and (-)-epicatechin (42.2 %), (-)-epigallocatechin gallate (7.8 %), non-21 
galloylated dimeric procyanidins B1, B2, B3, B4 (42.1 %), galloylated dimeric 22 
procyanidins B2-3-O-gallate and B2-3’-O-gallate (1.0 %), and trimeric procyanidins C1 23 
and T2 (4.1%). Non-flavonoid compounds such as gallic acid accounted for 2.7 % of 24 
total individual phenolic compounds quantified. 25 
 10 
In order to follow progress of the in vitro fermentations of the grape seed extract with 1 
faecal microbiota, both precursor phenolic compounds and microbial phenolic 2 
metabolites were targeted during the time course of different experiments. Changes in 3 
the flavan-3-ol profile originally present in the grape seed extract referred to flavan-3-4 
ols monomers ((+)-catechin, (-)-epicatechin and (-)-epigallocatechin gallate) (Figure 1), 5 
dimeric procyanidins (B1, B2, B3, B4, B2-3-O-gallate and B2-3’-O-gallate), and 6 
trimeric procyanidins (C1 and T2) (Figure 2). During the fermentations, a progressive 7 
decline in the concentration of flavan-3-ols was observed, showing very large 8 
interindividual variation among volunteers. For non-galloylated monomers, (+)-catechin 9 
and (-)-epicatechin, volunteers 2 and 3 (V2 and V3) showed faster degradation rate than 10 
volunteer 1 (V1), showing almost complete degradation (  92 %) of these substrates 11 
during the first 10 h of fermentation, whereas for V1 this was attained at 24 h (Figures 12 
1A and 1B) . The slower degradation rate of V1 was also observed in the case of non-13 
galloylated dimers B1, B2 and B3 and trimers C1 and T2, independently of the 14 
structural conformation (Figures 2A-D, 2G and 2H). However, similarity in the 15 
monomeric flavan-3-ol profile observed for V2 and V3 was not seen for these 16 
compounds, in particular at 5 h of fermentation, time at which V3 showed an 17 
unexpected increase in the level of each of these dimeric and trimeric precursors. A 18 
marked increase was also observed for procyanidin B4 for the three volunteers (V1 at 19 
10 h, and V2 and V3 at 5 h).  Transient increases in the concentration of trimeric and 20 
tetrameric procyanidins, during batch culture fermentations have also been described in 21 
previous studies performed with a cocoa flavan-3-ol extract (Tzounis, Rodriguez-22 
Mateos, Vulevic, Gibson, Kwik-Uribe & Spencer). Despite these findings, procyanidins 23 
were practically completed degraded by the 10 h of fermentation, as observed for 24 
monomers. 25 
 11 
Regarding galloylated flavan-3-ols, changes were observed in the degradation profile of 1 
volunteers in comparison to non-galloylated flavan-3-ols. For example, V1, who 2 
showed the lowest rate of degradation of non-galloylated flavan-3-ols, presented a fast 3 
degradation of both monomeric ((-)-epicatechin-3-O-gallate) and dimeric (B2-3-O-4 
gallate and B2-3’-O-gallate) galloylated forms, and comparable to that observed for V2, 5 
whereas V3 was a rather slow biotransformer of these compounds. These findings 6 
suggest possible variations in the metabolic activity of the microbiota, particularly in 7 
esterase activity (i.e., tannase), among volunteers. This microbiota activity has been 8 
reported to occur during in vitro batch fermentations of green tea galloylated flavan-3-9 
ols (Kohri et al., 2003; Meselhy et al., 1997; Roowi et al., 2010; Takagaki et al., 2010).  10 
 11 
In summary, from the three volunteers, V2 was the only one that appeared to be a good 12 
biotransformer of both galloylated non-galloylated flavan-3-ols. In the case of 13 
monomers, the time-course degradation of this volunteer was satisfactorily adjusted to a 14 
logarithmic-Y square root-X model: 2.52716 - 1.08351* time (+)-catechin = e  (with R
2
=0.937 15 
and standard error of the estimate= 0.7828);  2.92131 - 1.26803* time (-)-epicatechin = e   (with 16 
R
2
=0.971 and standard error of the estimate=  0.607436); 17 
1.56667 - 1.2748* time (-)-epicatechin-3-O-gallate = e   (with R
2
=0.902 and standard error of 18 
the estimate= 1.1706).  Taking into consideration that the constant term of the equation 19 
(1.08 for (+)-catechin, 1.26 for (-)-epicatechin and 1.57 for (-)-epicatechin-3-O-gallate) 20 
is indicative of the rate of degradation, it seems that for V2, (+)-catechin is degraded 21 
slightly slower than (-)-epicatechin and its gallic acid ester, but there was no apparent 22 
influence of galloylation in the rate of degradation of monomeric flavan-3-ols.  23 
 24 
 12 
Changes in microbial phenolic metabolites during faecal fermentation of the grape 1 
seed extract 2 
The catabolic pathway of flavan-3-ols, which is still under elucidation, is very complex 3 
involving numerous reactions (hydrolysis, hydrogenation, - and -oxidation, 4 
dehydroxylation, demethoxylation, decarboxylation) that result in the formation of a 5 
wide range of phenolic and aromatic catabolites, many of which may not yet have been 6 
identified. A total of 47 potential phenolic metabolites including, 7 
hydroxyphenylpropionic, hydroxyphenylacetic, hydroxycinnamic, hydroxybenzoic and 8 
hydroxymandelic acids, as well as simple phenols, were targeted by UPLC-DAD-ESI-9 
TQ MS during the time course of batch fermentations, as described by Sánchez-Patán et 10 
al. (Sánchez-Patán et al., 2011). In addition, characteristic metabolites exclusively 11 
derived from the catabolism of flavan-3-ols such as phenyl- -valerolactones and 12 
phenylvaleric acid derivatives, were also screened. From all targeted metabolites, 13 
methoxylated metabolites including 3-O- and 4-O-methyl gallic acids, 4-hydroxy-3-14 
methoxy-phenylacetic acid, syringic, vanillic and ferulic acids, as well as other phenolic 15 
acids such as p-coumaric, caffeic and protocatechuic acids, were only detected at trace 16 
levels that were under the limits of quantification of our method (Sánchez-Patán et al., 17 
2011).  18 
 19 
Phenyl- -valerolactone and 4-hydroxy-5-(phenyl)-valeric acid derivatives 20 
The first steps in the microbial degradation of flavan-3-ols involve reductive cleavage of 21 
the heterocyclic C-ring resulting in the formation of diphenylpropan-2-ols, which by 22 
further breakdown of the A-ring and lactonization results in phenylvalerolactones 23 
derivatives (Groenewoud & Hundt, 1986; Meselhy et al., 1997). As an intermediate 24 
metabolite, 1-(3’,4’-dihydroxyphenyl)-3-(2”, 4”, 6”-trihydroxyphenyl)-propan-2-ol was 25 
 13 
only detected at trace levels at 10 h of fermentation (data not shown). However, the 1 
formation of 5-(3’,4’-dihydroxyphenyl)- -valerolactone was clearly detected and started 2 
to be registered between 0-5 h of fermentation reaching a maximum concentration at 10 3 
h (Figure 3A), time period which coincided with an almost total disappearance of 4 
precursor flavan-3-ols (Figure 1 and 2). Results from in vitro studies have shown that 5 
the time at which the maximum formation of 5-(3’,4’-dihydroxyphenyl)- -valerolactone 6 
occurs (Tmax) is largely variable and could also be affected by the flavan-3-ol structure 7 
of the precursor compound and type of microbiota used (i.e, human or animal). Using 8 
human microbiota, Stoupi et al. (Stoupi et al., 2010) found that the maximum 9 
concentration of 5-(3’,4’-dihydroxyphenyl)- -valerolactone occurred at 12 h during the 10 
in vitro fermentation of procyanidin B2, although  it was detected much later (24 h) in 11 
the case of (-)-epicatechin. For (-)-epicatechin-3-O-gallate, the maximum production of 12 
this metabolite also occurred around 24 h (Meselhy et al., 1997). Other authors have 13 
reported that the Tmax of 5-(3’,4’-dihydroxyphenyl)- -valerolactone varied between 8-24 14 
h during the in vitro fermentation for green tea catechins [(-)-epicatechin, (-)-15 
epigallocatechin, or (-)-epigallocatechin-3-O-gallate]  (Roowi et al., 2010). Using rat 16 
faecal microbiota, only the 3’,5’-dihydroxylated form (i.e.,  5-(3’,5’-dihydroxyphenyl)-17 
-valerolactone) was detected and found as a minor product reaching Tmax at 69 h of 18 
fermentation (Takagaki et al., 2010).  19 
 20 
Large inter-individual variations were again observed among volunteers but coinciding 21 
with the fact that V1, the slower biotransformer of flavan-3-ols, also presented the 22 
lowest accumulation of 5-(3’,4’-dihydroxyphenyl)- -valerolactone. On the other hand, 23 
V3, which exhibited a transient increase at 5 h in the level of dimeric and trimeric 24 
procyanidins (Figure 2), also produced the highest level of this metabolite. In vivo 25 
 14 
studies have also reported large inter-individual variation in the urinary excretion of this 1 
metabolite after ingestion of tea (Li et al., 2000; Meng et al., 2002) and almond skin 2 
(Garrido et al., 2010; Llorach et al., 2010) polyphenols.   3 
 4 
The presence of 4-hydroxy-5-(3’,4’-dihydroxyphenyl)-valeric acid, the open form of 5-5 
(3’,4’-dihydroxyphenyl)- -valerolactone, was also detected, and gave a very similar 6 
profile to that of the 5-(3’,4’-dihydroxyphenyl)- -valerolactone (Figure 3B).  It has been 7 
proposed that these compounds could arise from the degradation of diphenylpropan-2-8 
ols, concurrently with the phenylvalerolactone form (Kohri et al., 2003). Recently, other 9 
authors have proposed that an interconversion between both forms (5-(3’,4’-10 
dihydroxyphenyl)- -valerolactone and 4-hydroxy-5-(3’,4’-dihydroxyphenyl)-valeric 11 
acid) may also exist, but being largely displaced towards the formation of  4-hydroxy-5-12 
(3’,4’-dihydroxyphenyl)-valeric acid (Stoupi et al., 2010). Metabolomic studies carried 13 
out with human urine samples after the intake of a flavan-3-ol-rich extract from almond 14 
skins also suggested that formation of these metabolites was largely interrelated 15 
(Llorach et al., 2010). Although this interconversion has not still been demonstrated to 16 
occur in vivo, recent studies have reported that the pH of extraction medium promotes 17 
chemical interconversion between both forms (Takagaki et al., 2010). 18 
 19 
 Due to large inter-individual differences observed among volunteers, it was difficult to 20 
establish the correct sequence of formation of 4-hydroxy-5-(3’,4’-dihydroxyphenyl)-21 
valeric acid. On one hand, the similarity in profile with 5-(3’,4’-dihydroxyphenyl)- -22 
valerolactone observed  for V1 and V2 suggests that 4-hydroxy-5-(3’,4’-23 
dihydroxyphenyl)-valeric acid could be formed together with former metabolite. 24 
However, on the other hand, the profile presented by V3 showing a further 25 
 15 
accumulation up to 24 h, suggests that the second pathway involving interconversion 1 
could also occur. In fact, three different pathways have been recently proposed for  the 2 
catabolism of (-)-epigallocatechin-3-O-gallate by rat intestinal microflora (Takagaki et 3 
al., 2010). Considering these facts, large differences in the occurrence (as well as the 4 
Tmax) of 4-hydroxy-5-(3’,4’-dihydroxyphenyl)-valeric acid have been reported varying 5 
with the structure of the flavan-3-ol precursor and type of microbiota, as in the case of 6 
5-(3’,4’-dihydroxyphenyl)- -valerolactone  (Stoupi et al., 2010; Takagaki et al., 2010). 7 
 8 
 Dehydroxylation reactions, which preferentially take place at position C-4’, occurred 9 
during later phase of the flavan-3-ol catabolism, leading to the formation 5-(3’-10 
hydroxyphenyl)- -valerolactone and 4-hydroxy-5-(3’-hydroxyphenyl)-valeric acid 11 
(Figure 3C and 3D, respectively). The trend of these two metabolites was very similar 12 
for each volunteer, showing a progressive increase up to 48 h of fermentation in the case 13 
of V1, and up to 30 h in the case of V3. However, for V2 the formation of both 14 
metabolites occurred earlier (up to 24 h) and markedly decreased afterwards. It is 15 
important to note change in the formation extent of these later metabolites shown by 16 
each volunteer in comparison to that of 5-(3’,4’-dihydroxyphenyl)- -valerolactone: V3 17 
now showed a lower/similar formation rate than V1, indicating possible differences in 18 
the metabolic activity (i.e. dehydroxalases) of the microbiota among volunteers. In any 19 
case, these trends indicate that dehydroxylation reactions certainly occur after the 20 
formation of 5-(3’,4’-dihydroxyphenyl)- -valerolactone and 4-hydroxy-5-(3’,4’-21 
dihydroxyphenyl)-valeric acid, and not from the flavan-3-ol compounds originally 22 
present in grape seed extract. This was further confirmed by the profile observed for 4-23 
hydroxy-5-(phenyl)-valeric acid (Figure 3G), which showed a much slower 24 
accumulation during the time-course of fermentation in the case of the three volunteers. 25 
 16 
However, the corresponding non-hydroxylated derivative of the lactone form, 5-1 
(phenyl)- -valerolactone (Figure 3F), was not detected. Instead, of particular interest 2 
was the detection of the simple -valerolactone metabolite, which tended to accumulate 3 
in the last phases of microbial fermentation up to 24 h (for V1 and V3) or in keeping 4 
with the profile observed for 5-(3’,4’-dihydroxyphenyl)- -valerolactone (for V2), 5 
indicating that the breakdown of the phenyl moiety may also occur as a consequence of 6 
microbial catabolism. As far as we are aware, this is the first time that -valerolactone is 7 
being reported as microbial metabolites derived from the catabolism of flavan-3-ols.  8 
 9 
Phenylpropionic and phenylacetic acid derivatives 10 
Parallel to the previous interconversion and dehydroxylation reactions, -oxidation of 11 
phenylvaleric acid derivatives are considered to occur resulting in phenylpropionic acid 12 
derivatives. During the in vitro fermentation of the grape seed extract, 3-(3,4-13 
dihydroxyphenyl)-propionic acid, which has been reported as one of the most abundant 14 
final microbial metabolites derived from the catabolism of flavan-3-ols, both  in vivo 15 
and in vitro (Gonthier et al., 2003a; Rios et al., 2003; Ward et al., 2004), was detected 16 
(Figure 4A). This metabolite showed a rapidly increase from 0 to 5 h of fermentation, 17 
reaching a peak level at 10 h and markedly declining at 24 h (in the case of V2 and V3), 18 
whereas V1  again showed a more discrete evolution trend. In contrast to our results, 19 
Stoupi et al. (Stoupi et al., 2010) reported that the formation of 3-(3,4-20 
dihydroxyphenyl)-propionic acid started to be registered much later (12 h and 24 h of 21 
the fermentation in the case (-)-epicatechin and procyanidin B2, respectively). It is of 22 
note that the profile observed was similar to that of 5-(3’,4’-dihydroxyphenyl)- -23 
valerolactone, indicating the possible coexistence of different catabolic pathways 24 
leading to formation of this metabolite, as proposed by Appeldoorn et al. (Appeldoorn 25 
 17 
et al., 2009). Nevertheless, some limitations of the batch culture models should also be 1 
considered when evaluating metabolite profiles, in particularly the fact that metabolites 2 
accumulated during fermentation, whereas in the in vivo case they are concurrently 3 
being produced and absorbed from the colonocytes. On the other hand, it is also of note 4 
that metabolomic studies carried out with urine collected after the intake of flavan-3-ols 5 
rich extracts by humans, revealed that the contribution of 3-(3’,4’-dihydroxyphenyl)-6 
propionic acid to urinary metabolome could occur very early (0-5 h after the intake) for 7 
its glucuronide conjugates, but later (10-24 h) for its sulfate conjugates (Llorach et al., 8 
2010).  9 
 10 
Dehydroxylation of 3-(3,4-dihydroxyphenyl)-propionic acid into 3-(3-hydroxyphenyl)-11 
phenylpropionic acid further occurred during the time course of fermentation, leading to 12 
a marked increase in concentration of this metabolite from 10-24 h (Figure 4C). It is of 13 
note that the evolution trend of 3-(3-hydroxyphenyl)-propionic acid observed for each 14 
volunteer was very similar to that of their corresponding phenyl- -valerolactone 15 
derivative, suggesting once again a high dehydroxylation activity for the microbiota of 16 
V1 and V2, in comparison to that of V3. Some other metabolites resulted from 17 
dehydroxylation reactions, in particularly 3-(4-hydroxyphenyl)-propionic acid and 18 
phenylpropionic acid (non-hydroxylated form) (Figure 4E and 4G), were also found to 19 
be formed during the fermentation of the basal medium (Online Supporting 20 
Information, Figure S1A, for phenylpropionic acid), as has been reported in previous in 21 
vitro experiments (Gross et al., 2010). These metabolites have been reported to be 22 
intermediate products of  metabolic pathway of phenylalanine (Curtius, Mettler & 23 
Ettlinger, 1976).  24 
  25 
 18 
Another important series of microbial metabolites are phenylacetic acid derivatives. 1 
These metabolites are considered to arise from the -oxidation of phenylpropionic acid 2 
derivatives (Meselhy et al., 1997; Stoupi et al., 2010), although an alternative pathway 3 
supports that they could exclusively arise from the microbial cleavage of the top unit of 4 
dimeric procyanidins (Appeldoorn et al., 2009). The evolutionary trend of 3,4-5 
dihydroxyphenylacetic acid was near to that of 3-(3,4-dihydroxyphenyl)-propionic acid, 6 
suggesting once again concurrent formation rather than posterior (Figure 4B). Previous 7 
in vitro studies have shown that the evolution trend of 3,4-dihydroxyphenylacetic acid 8 
largely varies depending on the original substrate to be fermented, green or black tea 9 
(Gao et al., 2006). Dehydroxylation at C-4 leads to the production of 3-10 
hydroxyphenylacetic acid, which showed an increase from 10 to 24 h of fermentation, 11 
particularly in V2 (Figure 4D). On the other hand, the product resulting from the 12 
dehydroxylation at C-3 (4-hydroxyphenylacetic acid) (Figure 4F) was shown to be 13 
largely formed from the fermentation of basal medium (Figure S1B). Similar  to this 14 
was the case of phenylacetic acid (Figure 4H and Figure S1C) (Gross et al., 2010). Both 15 
metabolites have been reported to be formed from the metabolism of certain aminoacids 16 
such as tyrosine and phenylalanine, respectively (Curtius et al., 1976). 17 
 18 
Benzoic acid derivatives and other metabolites 19 
Finally, benzoic acid derivatives are among the end products of the microbial 20 
catabolism of flavan-3-ols. They usually arise from the -oxidation of phenylpropionic 21 
acid derivatives. However, in the presence of galloylated flavan-3-ols, as is the case of 22 
grape seed extract, microbial esterase activity results in the formation of gallic acid 23 
during the initial phases of fermentation, as could be observed from its rapid increase in 24 
concentration from 0-5 h (Figure 5A), which is consistent with a sharp decline observed 25 
 19 
in monomeric and dimeric galloylated flavan-3-ols during the same period of time 1 
(Figures 1 and 2).  This profile is in agreement with that observed after the in vitro 2 
fermentation of black tea and green tea catechins (Gross et al., 2010; Roowi et al., 3 
2010). However, the posterior decarboxylation into pyrogallol was not detected in our 4 
study. Instead, catechol/pyrocatechol was detected from 10 h of fermentation on, 5 
progressively increasing up to 30 h in the case of V1 and V3, and up to 48 h for V2 6 
(Figure 5B).  7 
 8 
Other metabolites, including 4-hydroxybenzoic and benzoic acids were also detected 9 
during time-course of fermentation (Figures 5D and 5E, respectively). The origin of 4-10 
hydroxybenzoic acid seems to be more in line with its corresponding phenylpropionic 11 
acid derivative (Figure 4E). On the other hand, benzoic acid showed a non-uniform 12 
tendency during fermentation, but its formation partly aroused from the fermentation of 13 
the basal medium (data not shown). 4-Hydroxybenzoic and benzoic acids are important 14 
precursors of the hepatic metabolites 4-hydroxyhippuric and hippuric acids, 15 
respectively, which are among the most abundant end products of the metabolism of 16 
flavan-3-ols. 17 
 18 
Another metabolite which deserves consideration is 4-hydroxymandelic acid. Although 19 
this metabolite has been reported to arise from non-phenolic sources such as tyramine 20 
and similar biogenic amines (Scheline, 1991), we did not detected any formation of 4-21 
hydroxymandelic acid with the incubations carried out with the medium lacking the 22 
grape seed extract (data not shown), indicating that it arose from the microbial 23 
degradation of the grape seed flavan-3-ols. Recently, this metabolite has also been 24 
 20 
detected in human urine after the intake of red wine/red juice polyphenols (van Dorsten 1 
et al., 2009) , although its origin was not clearly attributed to polyphenols. 2 
 3 
Integrated summary of changes detected in the phenolic profile during faecal 4 
fermentation of the grape seed extract 5 
 6 
A Principal Component Analysis (PCA) was performed in order to summarize changes 7 
in the concentrations of both precursor flavan-3-ols and microbial phenolic metabolites 8 
resulting from the batch culture fermentation of the grape seed extract. Two principal 9 
components (PC1 and PC2), which explained 66.2 % of the total variance of the data, 10 
were obtained. To show the changes over time, scores of the samples in the different 11 
time periods (0, 5, 10, 24, 30 and 48 h) for the 3 volunteers were plotted in the plane 12 
defined by the first two principal components (Figure 6).  13 
 14 
The first principal component (PC1), explaining 54.8% of the total variance, was 15 
negatively correlated (loadings  -0.7) with precursor flavan-3-ols: (+)-catechin, (-)-16 
epicatechin, procyanidins B1, B2, B3 and B4, (-)-epicatechin-3-O-gallate, B2-3-O-17 
gallate, B2-3’-O-gallate, procyanidins C1 and T2. On the other hand, it was positively 18 
correlated (loadings  0.7) with the following microbial phenolic metabolites: 19 
catechol/pyrocatechol, 5-(3’-hydroxyphenyl)- -valerolactone, 4-hydroxy-5-(phenyl)-20 
valeric acid, 3-(3-hydroxyphenyl)-propionic acid, phenylpropionic acid, 4-21 
hydroxyphenylacetic acid and phenylacetic acid. Finally, the second principal 22 
component (PC2), explaining 11.4% of the total variance, was negatively correlated 23 
with 5-(3’, 4’-dihydroxyphenyl)- -valerolactone.  24 
 25 
 21 
Changes observed in PC1 values during first 10 h of fermentation were explained by 1 
precursor flavan-3-ols (negatively correlated with PC1), whereas as those occurring 2 
from 10-48 h were explained by microbial phenolic metabolites (positive correlated 3 
with PC1). In other words, PC1 reflected overall changes (decrease in precursor 4 
compounds and increase in microbial phenolic metabolites) occurring during the time-5 
course of the microbial catabolism of the grape seed extract.  In the case of PC2, 6 
negative values increased during the first 10 h of fermentation, indicating an increase in 7 
the concentration of 5-(3’, 4’-dihydroxyphenyl)- -valerolactone, which was the only 8 
compound negative correlated with this component. As fermentation time progressed 9 
from 10 h to 48 h, values in PC2 became positive and were indicative of the decreased 10 
observed in this metabolite during the latter phases of fermentation. It is of note that this 11 
component reflected a marked inter-individual variation in microbial catabolism of the 12 
grape seed extract, suggesting that formation of 5-(3’, 4’-dihydroxyphenyl)- -13 
valerolactone, as an intermediate metabolite, could be a critical step in the rate and 14 
extent of flavan-3-ol catabolism and therefore, in delimiting the absorption and further 15 
bioactivity of these compounds. Our findings reinforce the idea that 5-(3’,4’-16 
dihydroxyphenyl)- -valerolactone could be a potential biomarker of flavan-3-ols intake, 17 
as suggested from previous metabolomic studies (Llorach et al., 2010). However, as far 18 
as we are aware, there is still no reports of bacteria with the ability to form 5-(3’, 4’-19 
dihydroxyphenyl)- -valerolactone from the catabolism of flavan-3-ols. The human 20 
bacterium Eubacterium sp. SDG-2 was able to open the ring of the 3R [(-)-catechin and 21 
(-)-epicatechin] and the 3S [(+)-catechin and (+)-epicatechin] forms of monomeric 22 
flavan-3-ols into 1,3-diphenylpropan-2-ols, but was incapable of producing the same in 23 
their galloylated esters (Wang et al., 2001). However, this bacteria was unable to 24 
continue the catabolism up to the formation of 5-(3',4'-dihydroxyphenyl)- -25 
 22 
valerolactone (Wang et al., 2001). Apparently, structural features, including 1 
stereochemistry, as well as the own antimicrobial properties of flavan-3-ols, could have 2 
been a limitation in the progress of the identification of flavan-3-ol-metabolizing 3 
bacteria, which could be crucial in the activation of the microbial catabolism of flavan-4 
3-ols (Monagas et al., 2010). 5 
 6 
CONCLUDING REMARKS 7 
The approach of targeting both changes in precursor flavan-3-ols and microbial 8 
phenolic metabolites during faecal fermentation of the grape seed extract followed by 9 
the application multivariate statistical analysis, provided an overall picture of distinct 10 
phases of the microbial degradation of flavan-3-ols and helped to explain inter-11 
individual variations in microbial catabolism among volunteers. The first phase (0-10 h) 12 
was mainly characterized by the formation of the dihydroxylated forms of 5-(phenyl)- -13 
valerolactone and 4-hydroxy-5-(phenyl)-valeric acid derivatives and coincided with 14 
practically the total consumption of flavan-3-ol precursors by the faecal microbiota. 15 
Accumulation of the dihydroxylated forms of phenylpropionic and phenylacetic acids 16 
also occurred during this period. Final phases (10-48 h) involved dehydroxylation 17 
reactions of metabolites formed in early phases into their mono-hydroxylated, non-18 
hydroxylated forms, and even non-phenolic forms. Our results suggest that although the 19 
end products of  the microbial catabolism of flavan-3-ols are common to that of other 20 
flavonoids, the formation of intermediate characteristic metabolites such as  5-(3’, 4’-21 
dihydroxyphenyl)- -valerolactone, should be considered a key step in delimiting the rate 22 
and extent of flavan-3-ol bioavailability and potential bioactivity. 23 
 24 
 25 
 23 
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FIGURE LEGENDS 1 
 2 
Figure 1. Changes in monomeric flavan-3-ols during faecal fermentation of the grape 3 
seed extract. A) (+)-Catechin; B) (-)-Epicatechin, and C) (-)-Epicatechin-3-O-gallate. 4 
 5 
Figure 2. Changes in dimeric and trimeric procyanidins during faecal fermentation of 6 
the grape seed extract. A) B1; B) B2, C) B3; D) B4; E) B2-3-O-gallate; F) B2-3’-O-7 
gallate; G) C1, and H) T2.  8 
 9 
Figure 3. Changes in phenyl- -valerolactone and 4-hydroxy-5-(phenyl)-valeric acid 10 
derivatives during faecal fermentation of the grape seed extract. A) 5-(3’,4’-11 
Dihydroxyphenyl)- -valerolactone; B) 4-Hydroxy-5-(3’,4’-dihydroxyphenyl)-valeric 12 
acid; C) 5-(3’-Hydroxyphenyl)- -valerolactone; D) 4-Hydroxy-5-(3’-hydroxyphenyl)-13 
valeric acid; E) -Valerolactone; F) 4-Hydroxy-5-(phenyl)-valeric acid. 14 
 15 
Figure 4. Changes in phenylpropionic and phenylacetic acid derivatives during faecal 16 
fermentation of the grape seed extract. A) 3-(3,4-Dihydroxyphenyl)-propionic acid; B) 17 
3,4-Dihydroxyphenylacetic acid; C) 3-(3-Hydroxyphenyl)-propionic acid; D) 3-18 
Hydroxyphenylacetic acid; E) 3-(4-Hydroxyphenyl)-propionic acid; F) 4-19 
Hydroxyphenylacetic acid; G) Phenylpropionic acid; H) Phenylacetic acid. 20 
 21 
Figure 5. Changes in benzoic acid derivatives and other metabolites during faecal 22 
fermentation of the grape seed extract. A) Gallic acid; B) Catechol/pyrocatechol; C) 4-23 
Hydroxymandelic acid 4-; D) 4-Hydroxybenzoic acid; E) Benzoic acid. 24 
 25 
 28 
Figure 6. Representation of the samples in the plane defined by the first two principal 1 
components (PC1 and PC2) resulted from a PCA of both precursor flavan-3-ols and 2 
microbial-derived phenolic metabolites for three volunteers (V1, V2, V3) at different 3 
incubation times (0, 5, 10, 24, 30 and 48 h). 4 
5 
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Table 1.  Phenolic composition of the Vitaflavan  grape seed extract. 1 
  mg/g 
Gallic acid 9.11  0.01 
(+)-Catechin 74.57  0.09 
(-)-Epicatechin 67.68  0.75 
(-)-Epicatechin-3-O-gallate 26.21  0.41 
B1 60.99  1.42 
B2 45.13  0.95 
B3 20.39  0.33 
B4 15.04  0.13 
 B2-3-O-gallate 1.80  0.06 
 B2-3’-O-gallate 1.61  0.01 
C1 7.07  0.08 
T2 6.81  0.06 
Mean value (n=3)  SD 2 
 30 
Table 2.  MS/MS parameters, injection range, limit of detection (LOD) and quantification (LOQ) of the monomeric and dimeric flavan-3-ols. 1 
 2 
Name  MW Rt (min) Transition (m/z) Cone (V) Collision (V) Injection range ( g/mL) LOD ( g/mL) LOQ ( g/mL) 
(+) -Catechin 290 3.84 289>245 40 16 0.005-50 0.005 0.016 
(-) -Epicatechin 290 5.27 289>245 38 14 0.005-50 0.010 0.025 
(-)-Epicatechin-3-O-gallate 442 7.11 441>289 38 14 0.0025-25 0.009 0.023 
B1 578 3.56 577>289 45 25 0.0025-25 0.004 0.009 
B2 578 4.68 577>289 45 25 0.0025-25 0.012 0.027 
C1 866 5.69 865>577 50 25 0.01-100 0.090 0.200 
 3 
